ADILAdial Pharmaceuticals, Inc.

ADIL Stock Price, Valuation & Chart | Adial Pharmaceuticals, Inc.

Compare

$6.320+0.37 (+6.22%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology ADIL intrinsic value ADIL calculated fair value vs price

Overview Financials Dividends Ratios

ADIL Historical price chart

ADIL Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization6.06M

PE Ratio-0.38

EPS-16.54

Trading Volume53.68K

Today's High/Low6.49/5.75

Dividend Yield0.00

52 Week High/Low10.75/1.31

Shares Outstanding959.64K

ADIL Financial Statement

ADIL Analyst ratings

ADIL Analysis & performance metrics

ADIL Company profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related…

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for…

ADIL Management team

Name

Position

Brigette Robertson M.D.

Acting Chief Medical Officer

John R. Martin J.D.

Chief Legal Officer

Cary John Claiborne MBACEO

Chief Executive Officer, President & Director

Vinay Shah A.C.A., M.B.A.CFO

Chief Financial Officer & Treasurer

Andrew Taubman

Vice President of Corporate Development

Abel Svitavsky CPA

Controller

Tony GoodmanCOO

Chief Operating Officer & Director

Name

Position

Brigette Robertson M.D.

Acting Chief Medical Officer

John R. Martin J.D.

Chief Legal Officer

Cary John Claiborne MBACEO

Chief Executive Officer, President & Director

Vinay Shah A.C.A., M.B.A.CFO

Chief Financial Officer & Treasurer

Andrew Taubman

Vice President of Corporate Development

Abel Svitavsky CPA

Controller

Tony GoodmanCOO

Chief Operating Officer & Director

Management Team

Brigette Robertson M.D.

Acting Chief Medical Officer

John R. Martin J.D.

Chief Legal Officer

Cary John Claiborne MBACEO

Chief Executive Officer, President & Director

Vinay Shah A.C.A., M.B.A.CFO

Chief Financial Officer & Treasurer

Andrew Taubman

Vice President of Corporate Development

Abel Svitavsky CPA

Controller

Tony GoodmanCOO

Chief Operating Officer & Director

Management

Brigette Robertson M.D.

Acting Chief Medical Officer

John R. Martin J.D.

Chief Legal Officer

Cary John Claiborne MBACEO

Chief Executive Officer, President & Director

Vinay Shah A.C.A., M.B.A.CFO

Chief Financial Officer & Treasurer

Andrew Taubman

Vice President of Corporate Development

Abel Svitavsky CPA

Controller

Tony GoodmanCOO

Chief Operating Officer & Director

Total 7 executives

ADIL Frequently asked questions

What is Adial Pharmaceuticals, Inc. (ADIL) Stock Price?

Current stock price of Adial Pharmaceuticals, Inc. (ADIL) stock is $6.320. The stock price is +6.22% higher in the session. The intraday range can be seen from this page. Volume of Adial Pharmaceuticals, Inc. (ADIL) stock is 53.68K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Adial Pharmaceuticals, Inc. (ADIL) stock price going up or down today?

The stock price of Adial Pharmaceuticals, Inc. (ADIL) can change with earnings, company news, and overall market sentiment. Adial Pharmaceuticals, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Adial Pharmaceuticals, Inc. stock expensive at its current price?

Whether Adial Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ADIL on this page is -0.38. EPS on this page is -16.54. Compare those figures with peers and growth expectations before deciding if the current Adial Pharmaceuticals, Inc. price is justified.

How has the stock price of Adial Pharmaceuticals, Inc. (ADIL) performed historically?

Historical performance for Adial Pharmaceuticals, Inc. (ADIL) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ADIL reacted to past earnings and market events.

Should I buy Adial Pharmaceuticals, Inc. (ADIL) stock, at this price?

Buying Adial Pharmaceuticals, Inc. (ADIL) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.